Year: 2022

SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

Written by Customer Service on December 8, 2022. Posted in Public Companies.

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committee (IDMC) for its Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) performed its initial prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. The charter for the IDMC provides for periodic reviews by the IDMC for safety, efficacy and futility in addition to the interim and final analyses. The REGAL study is a Phase 3 open-label registrational clinical trial for GPS in AML patients who have achieved complete remission...

Kearny Financial Corp. Announces Wholesale Restructuring and Adoption of Operating Efficiency Initiative

Written by Customer Service on December 8, 2022. Posted in Public Companies.

FAIRFIELD, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) — Kearny Financial Corp. (NASDAQ GS: KRNY) (the “Company”), the holding company of Kearny Bank (the “Bank”), announced today the completion of a wholesale restructuring related to its investment securities portfolio. In addition, the Company announced the adoption of a company-wide operating efficiency initiative. Wholesale Restructuring The Company executed the sale of $121.4 million of its lower-yielding available-for-sale debt securities for an estimated after-tax loss of approximately $11.0 million. Proceeds from the sale were reinvested in debt securities currently yielding, on average, 440 basis points higher than the securities that were sold. In addition, the Company purchased approximately $100.0 million of debt securities, funded by wholesale borrowings, which will produce...

T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy

Written by Customer Service on December 8, 2022. Posted in Public Companies.

LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America. “We are grateful to these distinguished authors for reinforcing the CDC’s call for adoption and implementation of early and accurate microbial diagnosis to guide targeted antimicrobial treatment, directly aligning with the value proposition of T2’s technology,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “Sepsis continues to exact a heavy human and financial toll, and disproportionally impacts minorities and underserved communities. We believe our FDA-cleared T2Dx Instrument, T2Bacteria...

Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

Written by Customer Service on December 8, 2022. Posted in Public Companies.

Expands Commercialization Efforts in Areas with High Unmet Needs IRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for the EZ Detect™ Colon Disease test and the Aware® Breast Self Exam device. The Company is working with distribution partners to launch the products in these countries and throughout the Middle East and North Africa (MENA) regions. The EZ Detect™ Colon Disease Test is a simple two-minute at-home test for detecting hidden blood in the stool, a primary early warning sign of colorectal cancer. It’s the only test with no stool handling and suitable for national screening campaigns due to its convenience...

Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Written by Customer Service on December 8, 2022. Posted in Public Companies.

MINNEAPOLIS, Dec. 08, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company’s Special Meeting of Stockholders, on December 7, 2022 at 2:00 p.m. (CST), was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum consists of one-third of the outstanding shares entitled to vote. There were fewer than one-third of outstanding shares entitled to vote, either present virtually or represented by proxy, at the Special Meeting. The Special Meeting therefore had no quorum and was adjourned to 2:00 p.m. Central Time on January 4, 2023 at www.viewproxy.com/nuwesm/2022 to allow additional time for the Company’s stockholders to vote on the proposals set forth in the...

Anders Örnulf is leaving as CFO for SkiStar

Written by Customer Service on December 8, 2022. Posted in Public Companies.

SkiStar AB (publ)’s CFO Anders Örnulf has today announced that he will terminate his employment with SkiStar for a new assignment for another company. Anders, who has been SkiStar’s CFO since 2018, will continue in his position as CFO until a successor takes office, or until June 2023 at the latest. SkiStar will immediately start the recruitment process of a replacement. “During his five years at SkiStar, Anders Örnulf has had a prominent role in the company’s development, especially in such a turbulent period as the pandemic has brought. I would like to extend a big thank you to Anders, who is highly valued both as a skilled CFO for the company and as a colleague. We wish him all the best when he later leaves SkiStar,” says Stefan Sjöstrand, CEO at SkiStar. “My time at SkiStar has been extremely stimulating and...

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Written by Customer Service on December 8, 2022. Posted in Public Companies.

Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster presentation at the British Society for Immunology Congress 2022 OCALA, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today reported that data were recently presented by Lisanne C.A. Smidt – Centre for Human Drug Research (CHDR), Leiden, the Netherlands in a poster titled, “Safety, tolerability and biological activity...

Form 8.3 – [EMIS Group plc – 07 12 2022] – (CGAML)

Written by Customer Service on December 8, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED formerly HARGREAVE HALE LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree EMIS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Energy Management Systems Market Size Projected to Grow $75.0 Billion by 2027 growing at a CAGR of 14.2%

Written by Customer Service on December 8, 2022. Posted in Dividend Reports And Estimates.

Chicago, Dec. 08, 2022 (GLOBE NEWSWIRE) — Energy Management Systems Market is projected to grow from USD 38.6 billion in 2022 to USD 75.0 billion by 2027, at a CAGR of 14.2% according to a new report by MarketsandMarkets™. The growth of the energy management systems market is proportional to the installation of smart grids and smart meters. Also, the increasing energy consumption as well as the price volatility of energy resources plays a major role in driving the growth of energy management systems. The energy management systems market is expected to witness significant growth during the forecast period. With such a high demand for energy resources, the volatility in energy prices centers on changes in supply and demand. Economic conditions, availability of energy resources, and increasing demand are the prime factors...

Alm. Brand A/S – Award of share-based remuneration

Written by Customer Service on December 8, 2022. Posted in Public Companies.

Alm. Brand – Award of share-based remuneration In accordance with the Alm. Brand Group’s remuneration policy Alm. Brand A/S, effective from 1 July 2016, has entered into an agreement with the Management Board and other members of the group’s extended management team under which up to 10% of the fixed salary may be allotted by way of shares. Shares are awarded twice annually, on the third trading day of June and the third trading day of December. The value of the awarded shares has been calculated as a simple average of the average price quoted for one share on the first trading day of each calendar month forming the basis of the award. A total of 486,087 shares representing a total market value of DKK 5,137,939.59 have been awarded. The shares are freely negotiable instruments. The agreement on share-based remuneration applies until...

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals